Systematic analyses of genes associated with radio sensitizing effect by celecoxib, a specific cyclooxygenase-2 inhibitor

Journal of Radiation Research

Volumn 52, Issue 6, 2011, Pages 752-765

  Kim, Young Mee ^a   Shin, You Keun ^b   Jun, Hyun Jung ^a,c   Rha, Sun Young ^b   Pyo, Hongryull ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

cDNAmicroarray; Celecoxib; COX 2; Ionizing radiation; siRNA

Indexed keywords

CELL CULTURE; ENZYME ACTIVITY; GENE EXPRESSION; RADIATION SHIELDING;

CANCER CELLS; CDNAMICROARRAY; CELECOXIB; COX-2; CYCLO-OXYGENASE-2 INHIBITOR; RADIATION TREATMENTS; SENSITIZING EFFECTS; SIRNA; SPECIFIC INHIBITORS; SYSTEMATIC ANALYSIS;

IONIZING RADIATION;

EID: 82055187099     PISSN: 04493060     EISSN: 13499157     Source Type: Journal    
DOI: 10.1269/jrr.10146     Document Type: Article

References (37)

1. Rao P and Knaus E-E (2008) Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 11: 81s-110s.
2. Lou J, et al (2006) Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells. Cancer Epidemiol Biomarkers Prev 15: 1598-1606.
3. Huang R-H, Chai J and Tarnawski AS (2006) Identification of specific genes and pathways involved in NSAIDs-induced apoptosis of human colon cancer cells. World J Gastroenterol 12: 6446-6452.
4. Glebov O-K, et al (2006) Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 15: 1382-1391.
5. Grosch S, et al (2006) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98: 736-747.
6. Auman J-T, et al (2008) Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur J Cancer 44: 1754-1760.
7. Brown J-R and DuBois R-N (2005) COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23: 2840-2855.
8. John-Aryankalayil M, et al (2009) NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells. Mol Cancer Ther 8: 261-273.
9. Fatima N, et al (2008) Altered gene expression profiles define pathways in colorectal cancer cell lines affected by celecoxib. Cancer Epidemiol Biomarkers Prev 17: 3051-3061.
10. Harris R-E (2009) Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17: 55-67.
11. Handrick R, et al (2009) Combined action of celecoxib and ionizing radiation in prostate cancer cells is independent of pro-apoptotic Bax. Radiother Oncol 90: 413-421.
12. Fakih M-G and Rustum Y-M (2009) Does celecoxib have a role in the treatment of patients with colorectal cancer? Clin Colorectal Cancer 8: 11-14.
13. Fatima N, et al (2009) Label-free global serum proteomic profiling reveals novel celecoxib-modulated proteins in familial adenomatous polyposis patients. Cancer Genomics Proteomics 6: 41-49.
14. Garman K-S, et al (2008) A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci USA 105: 19432-19437.
15. Shin Y-K, et al (2005) Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 65: 9501-9509.
16. Park J-S, et al (2006) Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells. Clin Cancer Res 12: 4989-4999.
17. Kim Y-M, et al (2009) Cyclooxygenase-2 up-regulates ataxiatelangiectasia and Rad3 related through extracellular signal-regulated kinase activation. Mol Cancer Res 7: 1158-1168.
18. Kang H-K, et al (2005) Cyclooxygenase-independent down-regulation of multi-drug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol CancerTher 4: 1358-1363.
19. Yang S-H, et al (2003) Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Int J Oncol 22: 741-750.
20. Rocke D-M and Durbin B (2001) A model for measurement error for gene expression arrays. J Comput Biol 8: 557-569.
21. Kim Y-M, Park S-Y and Pyo H (2009) Cyclooxygenase-2 (COX-2) Negatively Regulates Expression of Epidermal Growth Factor Receptor and Causes Resistance to Gefitinib in COX-2-Overexpressing Cancer Cells. Mol Cancer Res 7: 1367-1377.
22. Hussein D and Taylor S-S (2002) Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci 115: 3403-3414.
23. Caillaud M-C, et al (2009) Spindle assembly checkpoint protein dynamics reveal conserved and unsuspected roles in plant cell division. PLoS One 4: e6757.
24. Chiche J, et al (2009) Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 69: 358-368.
25. Milia J, et al (2005) Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication. Cell Death Differ 12: 492-501.
26. Ader I, et al (2002) RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death. Oncogene 21: 5998-6006.
27. Jun H-J, et al (2009) Modulation of ionizing radiation-induced G2 arrest by cyclooxygenase-2 and its inhibitor celecoxib. Int J Radiat Oncol Biol Phys 75: 225-234.
28. Tseng W-W, et al (2002) Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J Gastrointest Surg 6: 838-843; discussion 844.
29. Hardwick J-C, et al (2004) DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1. Carcinogenesis 25: 1293-1298.
30. Sagiv E, et al (2007) Gene expression analysis proposes alternative pathways for the mechanism by which celecoxib selectively inhibits the growth of transformed but not normal enterocytes. Clin Cancer Res 13: 6807-6815.
31. Kim Y-M and Pyo H (2011) Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) and celecoxib in human lung and colon cancer cell lines. DNA AND CELL BIO Accepted.
32. Ethridge R-T, et al (1998) Inhibition of heat-shock protein 70 induction in intestinal cells overexpressing cyclooxygenase 2. Gastroenterology 115: 1454-1463.
33. Zhao R, et al (2005) Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 120: 715-727.
34. Burikhanov R, et al (2009) The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 138: 377-388.
35. Zhang Z and DuBois R-N (2000) Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology 118: 1012-1017.
36. Pyo H, et al (2001) A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 7: 2998-3005.
37. Jun H-J, et al (2009) Modulation of ionizing radiation-induced G2 arrest by cyclooxygenase-2 and its inhibitor celecoxib. Int J Radiat Oncol Biol Phys 75: 225-234.